Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's. Find out why AVXL stock is a Sell.

The two countries employ 70 percent of the world’s top machine learning researchers, command 90 percent of global computing power, and attract the vast majority of AI investment—more than twice the ...

The public release improves audio, speech, debugging, and developer experience. Additionally, a more cost-effective mini ...

Medpace's backlog growth remains sluggish, but a healthy book-to-bill ratio and potential sector recovery could accelerate ...